Due to a measles case in the community, please call before coming to Seattle Children’s if you or your child has potential measles symptoms.

Current Research Studies

A Phase 1b/2a Study To Evaluate The Safety Of CMTX-101 In Combination With Standard Of Care Inhaled Antipseudomonal Therapy In People With Cystic Fibrosis Chronically Infected With Pseudomonas aeruginosa

Clarametyx Phase1B/2A in Cystic Fibrosis

Condition: Pulmonary
Phase: I/II

What is the goal of the study?

A phase 1B/2A clinical trial of a monoclonal antibody targeted to Pseudomonas aeruginosa, a common pathogen in lung infections in people with cystic fibrosis. The clinical trial will be conducted in participants who are 18 years of age and older. The investigational product will be administered intravenously with blood collected for pharmacokinetic assays and safety assessments. Standard of care treatment will be maintained. Adverse events will be monitored through the clinical trial.

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team:

PI (Study Doctor): Ronald Gibson

Seattle Children’s complies with applicable federal and other civil rights laws and does not discriminate, exclude people or treat them differently based on race, color, religion (creed), sex, gender identity or expression, sexual orientation, national origin (ancestry), age, disability, or any other status protected by applicable federal, state or local law. Financial assistance for medically necessary services is based on family income and hospital resources and is provided to children under age 21 whose primary residence is in Washington, Alaska, Montana or Idaho.